Abstract | BACKGROUND AND AIMS: METHODS: We reviewed the records from the inflammatory bowel disease (IBD) center at Lenox Hill Hospital and one large IBD practice in New York City of 334 patients treated with 6-MP for UC. These patients were followed from 4 months to 28.7 yr. Sixty-one patients were treated with 6-MP for at least 6 months and had at least a 3-month disease-free interval off steroids while on the medication. These patients were divided into two groups: Group 1 continued 6-MP and group 2 discontinued the drug at various times for reasons other than relapse. Time to relapse was calculated for both groups. RESULTS: A Kaplan-Meier survival analysis was employed and differences between the two groups were analyzed using the log-rank test. The median time to relapse in group 2 was 24 wk and in group 1 was 58 wk (p < 0.05). There were no significant differences between the two groups in age, gender, extent of disease, use of concomitant 5-ASA products, dose of 6-MP during remission, duration of UC, and duration of treatment with 6-MP before remission was achieved. CONCLUSION: Discontinuation of treatment with 6-MP while UC is in remission leads to a higher relapse rate than maintenance on 6-MP. Therefore, we favor the indefinite treatment with 6-MP in most patients.
|
Authors | Efrat Z Lobel, Burton I Korelitz, Mark A Xuereb, Georgia Panagopoulos |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 99
Issue 3
Pg. 462-5
(Mar 2004)
ISSN: 0002-9270 [Print] United States |
PMID | 15056086
(Publication Type: Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Mercaptopurine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Colitis, Ulcerative
(drug therapy)
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Mercaptopurine
(therapeutic use)
- Middle Aged
- Recurrence
- Time Factors
|